Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimations dated 11th May, 2023 and 12th May, 2023 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request/application from the registered shareholder(s) of the Company for i) issue of Duplicate Share Certificate(s) for the purpose of claiming the shares from the Investor Education and Protection Fund (IEPF) and ii) issue of Duplicate Share Certificate(s).
12-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our Solid Oral Formulation Facility (F-4) at Jarod, Vadodara during the period from 8th December, 2022 to 16th December, 2022. This was pre-approval inspection to cover our Solid Oral drug products for which ANDAs were filed with USFDA. The Company had also started receiving approvals manufactured at this facility. Alembic has a total of five drug product manufacturing facilities and two drug substance manufacturing facilities. All these facilities are inspected and accepted by USFDA.
10-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimations dated 9th May, 2023 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding approval of the request received for issue of Duplicate Share Certificate(s) and issue of letter of confirmation in lieu of the physical share certificate to the registered shareholder(s) in accordance with the provisions of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022.
09-05-2023

Buy Alembic Pharma; target of Rs 704: KR Choksey

 KR Choksey is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 704 in its research report dated May 06, 2023.
08-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 With reference to the captioned matter, this is to inform the exchange that the audio recording has been hosted on the website of the Company and can be accessed at https://alembicpharmaceuticals.com/quarterly-results/
06-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Updated Contact Details Of Key Managerial Personnel / Senior Officials Pursuant To Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 With reference to the captioned matter, please find below the updated contact details of persons authorised for the purpose of determining materiality of an event or information and for making disclosures to the Stock Exchange, pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
05-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Change in Directorate

 With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at its meeting held on 5th May, 2023 has approved the appointment of Mr. Jai Diwanji (DIN: 00910410) as an Independent Director of the Company for a period of 5 (five) consecutive years w.e.f. 5th May, 2023, subject to approval of the members by way of a Special Resolution. We hereby declare that Mr. Jai Diwanji is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.
05-05-2023
Bigul

Alembic Pharmaceuticals Q4 net jumps three-fold at 131 cr

 Lower costs coupled with growth in API, and India branded business drive the growth
05-05-2023
Bigul

Q4FY23 Quarterly & FY23 Annual Result Announced for Alembic Pharmaceuticals Ltd.

 Alembic Pharmaceuticals announced Q4FY23 & FY23 results: Financial Highlights: Net Sales for the quarter at Rs 1,406 crore Net Profit for the quarter at Rs 153 crore Net sales for FY23 at Rs 5,653 crore Net profit for FY23 at Rs 342 crore Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The USA business continues to remain challenging, however, the Company witnessed topline growth across all other verticals. In particular, the API business outperformed with a 41% growth and Ex-US generics with a 33% growth during the quarter. We have started the commercialization of products from our injectable and oncology facilities. India Branded Business continues to outperform the market, especially on focused products / therapeutic segments". Result PDF
05-05-2023
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, please find enclosed herewith Press Release on the Audited Financial Results for the quarter and financial year ended 31st March, 2023.
05-05-2023
Next Page
Close

Let's Open Free Demat Account